시장보고서
상품코드
1150069

세계의 녹내장 시장-시장 점유율, 규모, 동향, 산업 분석 : 약제 클래스별, 유통 채널별, 질환 유형별, 지역별, 부문 예측(2022-2030년)

Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prostaglandin Analogs, Beta-blockers, Adrenergic Agonists, Carbonic Anhydrase Inhibitors); By Distribution Channel; By Disease Type; By Region; Segment Forecast, 2022-2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 117 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 녹내장 시장 규모는 2030년까지 97억 7,000만 달러에 달할 것으로 예측됩니다.

세계의 녹내장(Glaucoma) 시장을 조사했으며, 시장 개요/시장 규모 및 예측/동향/촉진 요인·억제 요인/약제 클래스별·유통 채널별·질환 유형별·지역별 분석/기업 개요 등 정보를 제공합니다.

목차

제1장 소개

  • 리포트 설명
    • 조사의 목적
    • 시장 범위
    • 전제 조건
  • 이해관계자

제2장 주요 요약

  • 시장의 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 정보원
    • 1차 정보
    • 2차 정보

제4장 세계의 녹내장 시장 통찰

  • 녹내장-산업 스냅샷
  • 녹내장 시장 역학
    • 촉진 요인과 기회
    • 억제 요인과 과제
  • Porter’s Five Forces
    • 공급기업의 협상력
    • 신규 참가자의 위협
    • 구매자의 협상력
    • 대체품의 위협
    • 기존 기업 간의 경쟁력
  • PESTEL 분석
  • 녹내장 시장의 산업 동향
  • 밸류체인 분석
  • COVID-19 영향 분석

제5장 세계의 녹내장 시장 : 약제 클래스별

  • 주요 조사 결과
  • 소개
    • 세계의 녹내장 시장, 약제 클래스별(2018-2030년)
  • 프로스타글란딘 유사체
    • 세계의 녹내장 시장, 프로스타글란딘 유사체별, 지역별(2018-2030년)
  • 베타 차단제
    • 세계의 녹내장 시장, 베타 차단제별, 지역별(2018-2030년)
  • 아드레날린 작용제
    • 세계의 녹내장 시장, 아드레날린 작용제별, 지역별(2018-2030년)
  • 탄산탈수효소 억제제
    • 세계의 녹내장 시장, 탄산탈수효소 억제제별, 지역별(2018-2030년)
  • 기타
    • 세계의 녹내장 시장, 기타별, 지역별(2018-2030년)

제6장 세계의 녹내장 시장 : 유통 채널별

  • 주요 조사 결과
  • 소개
    • 세계의 녹내장 시장, 유통 채널별(2018-2030년)
  • 병원 약국
    • 세계의 녹내장 시장, 병원 약국별, 지역별(2018-2030년)
  • 소매 약국
    • 세계의 녹내장 시장, 소매 약국별, 지역별(2018-2030년)
  • 온라인 약국
    • 세계의 녹내장 시장, 온라인 약국별, 지역별(2018-2030년)

제7장 세계의 녹내장 시장 : 질환 유형별

  • 주요 조사 결과
  • 소개
    • 세계의 녹내장 시장, 질환 유형별(2018-2030년)
  • 개방 각
    • 세계의 녹내장 시장, 개방 각, 지역별(2018-2030년)
  • 폐색 각
    • 세계의 녹내장 시장, 폐색 각, 지역별(2018-2030년)
  • 기타
    • 세계의 녹내장 시장, 기타별, 지역별(2018-2030년)

제8장 세계의 녹내장 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 녹내장 시장의 평가, 지역별(2018-2030년)
  • 녹내장 시장-북미
    • 북미 : 녹내장 시장, 약제 클래스별(2018-2030년)
    • 북미 : 녹내장 시장, 질환 유형별(2018-2030년)
    • 북미 : 녹내장 시장, 유통 채널별(2018-2030년)
    • 녹내장 시장-미국
    • 녹내장 시장-캐나다
  • 녹내장 시장-유럽
    • 유럽 : 녹내장 시장, 약제 클래스별(2018-2030년)
    • 유럽 : 녹내장 시장, 질환 유형별(2018-2030년)
    • 유럽 : 녹내장 시장, 유통 채널별(2018-2030년)
    • 녹내장 시장-영국
    • 녹내장 시장-프랑스
    • 녹내장 시장-독일
    • 녹내장 시장-이탈리아
    • 녹내장 시장-스페인
    • 녹내장 시장-네덜란드
    • 녹내장 시장-러시아
  • 녹내장 시장-아시아 태평양
    • 아시아 태평양 : 녹내장 시장, 약제 클래스별(2018-2030년)
    • 아시아 태평양 : 녹내장 시장, 질환 유형별(2018-2030년)
    • 아시아 태평양 : 녹내장 시장, 유통 채널별(2018-2030년)
    • 녹내장 시장-중국
    • 녹내장 시장-인도
    • 녹내장 시장-말레이시아
    • 녹내장 시장-일본
    • 녹내장 시장-인도네시아
    • 녹내장 시장-한국
  • 녹내장 시장-중동·아프리카
    • 중동·아프리카 : 녹내장 시장, 약제 클래스별(2018-2030년)
    • 중동·아프리카 : 녹내장 시장, 질환 유형별(2018-2030년)
    • 중동·아프리카 : 녹내장 시장, 유통 채널별(2018-2030년)
    • 녹내장 시장-사우디 아라비아
    • 녹내장 시장-아랍 에미리트 연방
    • 녹내장 시장-이스라엘
    • 녹내장 시장-남아프리카
  • 녹내장 시장-남미
    • 남미 : 녹내장 시장, 약제 클래스별(2018-2030년)
    • 남미 : 녹내장 시장, 질환 유형별(2018-2030년)
    • 남미 : 녹내장 시장, 유통 채널별(2018-2030년)
    • 녹내장 시장-멕시코
    • 녹내장 시장-브라질
    • 녹내장 시장-아르헨티나

제9장 경쟁 상황

  • 확대·인수 분석
    • 확대
    • 인수
  • 파트너십/협업/협정/전시

제10장 기업 개요

  • Allergan PLC
  • Aristo Pharmaceuticals Pvt. Ltd
  • Aerie Pharmaceuticals Company
  • Akorn operating company LLC
  • Bausch & Lomb Incorporated
  • Cipla Incorporation
  • Fera Pharmaceuticals, LLC
  • Inotek Pharmaceuticals
  • Merck KGaA
  • Novartis AG
  • Pfizer Incorporation
  • Santen Pharmaceutical Co., Ltd
  • Teva Pharmaceutical Industries Ltd
  • Valeant Pharmaceuticals International, Inc.
LYJ 22.11.30

The global glaucoma market size is expected to reach USD 9.77 billion by 2030, according to a new study by Polaris Market Research. The report "Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Prostaglandin analogs, Beta-blockers, Adrenergic agonists, Carbonic anhydrase inhibitors, and Others); By Distribution Channel; By Disease Type; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of glaucoma across the globe is the key factor bolstering market growth over the forecast period. Glaucoma is gradually becoming more common among the senior population. The elderly population's increased use of technology, such as smartphones and laptops, is contributing to the rise in glaucoma cases. As per the International Agency for the Prevention of Blindness, in the entire world, glaucoma is the third most common cause of blindness and the fourth most prevalent cause of visual loss.

According to estimates, at least 3 million people are currently blind, and 4 million have glaucoma-related mild to severe vision problems. At least 50 percent of glaucoma sufferers are not aware of their condition. 90% of glaucoma cases in some developing nations go undiagnosed.

Further, it also estimated that, in 2018, glaucoma affected 1.9% of Americans over 40 age. According to estimates, there will be 112 million cases of glaucoma by 2040, up from 76 million in 2020. Vision impairment has become a prominent public health issue as the world's population ages.

One billion people worldwide in 2020 have presbyopia or impaired distance vision. This number is projected to rise to 1/8 billion by 2050. In later life (>60 years), common causes of visual impairment, such as cataracts, glaucoma, age-related vision problems, diabetes mellitus, and presbyopia, are increasingly common.

The market for glaucoma is expanding at a remarkable rate, primarily because of the rising elderly population. The risk of glaucoma is most significant in the elderly population, yet it can also afflict people of other ages. People with diabetes and a history of glaucoma in their families are two more high-risk populations. Other market-driving drivers include rising awareness, rising healthcare costs, and screening.

Glaucoma Market Report Highlights

The clinics segment is anticipated to grow at a fastest CAGR over the forecast period. The number of glaucoma cases worldwide has increased, which has increased the demand for ophthalmic clinic treatments. The necessity for ophthalmology clinics in the medical sector has increased as a result of an increase in eye illnesses and technological advancements.

Beta blockers segment accounted for a significant revenue share in 2021. Due to their relative affordability, beta blockers are the most frequently chosen medication by patients. The market is seeing an increase in demand for beta-blocker eye drops due to rising treatment costs.

Asia Pacific is expected to witness fastest growth over the projected period. The market's demand for glaucoma medications has expanded as a result of rising government financing for the medical sector.

The global glaucoma market is highly competitive owing to the existence of large market players with a global presence including Allergan PLC, Bausch & Lomb Incorporated, Cipla Incorporation, Inotek Pharmaceuticals, Merck KGaA, Novartis AG, Pfizer Incorporation, Teva Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc.

Polaris Market Research has segmented the glaucoma market report based on drug class, distribution channel, disease type, and region:

Glaucoma, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)

Prostaglandin analogs

Beta-blockers

Adrenergic agonists

Carbonic anhydrase inhibitors

Others

Glaucoma, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital pharmacy

Retail pharmacy

Online Pharmacy

Glaucoma, Disease Type Outlook (Revenue - USD Billion, 2018 - 2030)

Open-angle glaucoma

Angle-closure glaucoma

Others

Glaucoma, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Glaucoma Market Insights

  • 4.1. Glaucoma - Industry Snapshot
  • 4.2. Glaucoma Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence Glaucoma to bolster market growth
      • 4.2.1.2. Increasing product under pipeline and recent product launches to accelerate growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Drug recalls by major players is projected to hinder demand for Glaucoma therapeutics
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Glaucoma Market Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Glaucoma Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 5.3. Prostaglandin Analogs
    • 5.3.1. Global Glaucoma Market, by Prostaglandin Analogs, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Beta-blockers
    • 5.4.1. Global Glaucoma Market, by Beta-blockers, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Adrenergic Agonists
    • 5.5.1. Global Glaucoma Market, by Adrenergic Agonists, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Carbonic Anhydrase Inhibitors
    • 5.6.1. Global Glaucoma Market, by Carbonic Anhydrase Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Other Glaucoma Market, by Region, 2018 - 2030 (USD Billion)

6. Global Glaucoma Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 6.3. Hospital pharmacy
    • 6.3.1. Global Glaucoma Market, by Hospital pharmacy, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Retail pharmacy
    • 6.4.1. Global Glaucoma Market, by Retail pharmacy, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Online Pharmacy
    • 6.5.1. Global Glaucoma Market, by Online Pharmacy, by Region, 2018 - 2030 (USD Billion)

7. Global Glaucoma Market, by Disease Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 7.3. Open-angle
    • 7.3.1. Global Glaucoma Market, by Open-angle, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Angle-closure
    • 7.4.1. Global Glaucoma Market, by Angle-closure, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Other Glaucoma Market, by Region, 2018 - 2030 (USD Billion)

8. Global Glaucoma Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Glaucoma Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 8.3. Glaucoma Market - North America
    • 8.3.1. North America: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.3.2. North America: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.3.3. North America: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.3.4. Glaucoma Market - U.S.
      • 8.3.4.1. U.S.: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.3.4.2. U.S.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.3.4.3. U.S.: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.3.5. Glaucoma Market - Canada
      • 8.3.5.1. Canada: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.3.5.2. Canada.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.3.5.3. Canada: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.4. Glaucoma Market - Europe
    • 8.4.1. Europe: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.4.2. Europe.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.4.3. Europe: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.4. Glaucoma Market - UK
      • 8.4.4.1. UK: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.4.2. UK.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.4.3. UK: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.5. Glaucoma Market - France
      • 8.4.5.1. France: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.5.2. France.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.5.3. France: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.6. Glaucoma Market - Germany
      • 8.4.6.1. Germany: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.6.2. Germany.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.6.3. Germany: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.7. Glaucoma Market - Italy
      • 8.4.7.1. Italy: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.7.2. Italy.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.7.3. Italy: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.8. Glaucoma Market - Spain
      • 8.4.8.1. Spain: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.8.2. Spain.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.8.3. Spain: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.9. Glaucoma Market - Netherlands
      • 8.4.9.1. Netherlands: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.9.2. Netherlands.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.9.3. Netherlands: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.4.10. Glaucoma Market - Russia
      • 8.4.10.1. Russia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.4.10.2. Russia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.4.10.3. Russia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.5. Glaucoma Market - Asia Pacific
    • 8.5.1. Asia Pacific: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.5.2. Asia Pacific.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.5.3. Asia Pacific: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.4. Glaucoma Market - China
      • 8.5.4.1. China: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.4.2. China.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.4.3. China: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.5. Glaucoma Market - India
      • 8.5.5.1. India: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.5.2. India.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.5.3. India: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.6. Glaucoma Market - Malaysia
      • 8.5.6.1. Malaysia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.6.2. Malaysia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.6.3. Malaysia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.7. Glaucoma Market - Japan
      • 8.5.7.1. Japan: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.7.2. Japan.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.7.3. Japan: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.8. Glaucoma Market - Indonesia
      • 8.5.8.1. Indonesia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.8.2. Indonesia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.8.3. Indonesia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.5.9. Glaucoma Market - South Korea
      • 8.5.9.1. South Korea: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.5.9.2. South Korea.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.5.9.3. South Korea: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.6. Glaucoma Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.6.2. Middle East & Africa.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.6.3. Middle East & Africa: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.4. Glaucoma Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.5. Glaucoma Market - UAE
      • 8.6.5.1. UAE: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.5.2. UAE.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.6.5.3. UAE: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.6. Glaucoma Market - Israel
      • 8.6.6.1. Israel: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.6.2. Israel.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.6.6.3. Israel: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.6.7. Glaucoma Market - South Africa
      • 8.6.7.1. South Africa: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.6.7.2. South Africa.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.6.7.3. South Africa: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 8.7. Glaucoma Market - Latin America
    • 8.7.1. Latin America: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 8.7.2. Latin America.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 8.7.3. Latin America: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.7.4. Glaucoma Market - Mexico
      • 8.7.4.1. Mexico: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.4.2. Mexico.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.7.4.3. Mexico: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.7.5. Glaucoma Market - Brazil
      • 8.7.5.1. Brazil: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.5.2. Brazil.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.7.5.3. Brazil: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 8.7.6. Glaucoma Market - Argentina
      • 8.7.6.1. Argentina: Glaucoma Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 8.7.6.2. Argentina.: Glaucoma Market, by Disease Type, 2018 - 2030 (USD Billion)
      • 8.7.6.3. Argentina: Glaucoma Market, by Distribution Channel, 2018 - 2030 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Allergan PLC
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Aristo Pharmaceuticals Pvt. Ltd
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Aerie Pharmaceuticals Company
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Akorn operating company LLC
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Bausch & Lomb Incorporated
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Cipla Incorporation
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Fera Pharmaceuticals, LLC
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Inotek Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Merck KGaA
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Novartis AG
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Pfizer Incorporation
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
  • 10.12. Santen Pharmaceutical Co., Ltd
    • 10.12.1. Company Overview
    • 10.12.2. Financial Performance
    • 10.12.3. Product Benchmarking
    • 10.12.4. Recent Development
  • 10.13. Teva Pharmaceutical Industries Ltd
    • 10.13.1. Company Overview
    • 10.13.2. Financial Performance
    • 10.13.3. Product Benchmarking
    • 10.13.4. Recent Development
  • 10.14. Valeant Pharmaceuticals International, Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Financial Performance
    • 10.14.3. Product Benchmarking
    • 10.14.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제